ARNA Genomics is an innovative biotechnological company, launched on the basis of the scientific and research laboratory and a team of like-minded people, engaged in development and research of early detection methods of oncological diseases with the purpose of launch of diagnostic tests for early cancer detection on the global market.
Our mission is to increase the life expectancy and significantly reduce human mortality by means of global market launch of most recent, unique in efficiency methods of screening (screening study with the purpose of detection and prevention of disease development in population), diagnostics (correct diagnosing) and monitoring of treatment process of oncological diseases.
ARNA Genomics company has discovered a technology which allows to develop tests for different types (nosologies) of cancer. Besides, the company has also developed a unique concept of blockchain based ecosystem, which will be used as an instrument to support R&D and implementation of biotechnologies worldwide.
We have completed R&D for the first product based on our technology – breast cancer test.
Colon cancer test is currently in R&D stage. Besides, we are currently developing a blockchain platform solution – ARNA Panacea, which will soon allow to change the world by making launch of new biotech solutions against cancer much easier and faster.
ARNA Panacea is platform which allows not processing of clinical trials data and also support for researchers during R&D phase and marketplace for all types of market participants involved in clinical trials as well as direct sales of final biotech products to customers (patients). The platform’s initial purpose is to gain, store and analyze information on all the methods of cancer detection and treatment from all over the world. This would allow researchers getting more accurate and precise knowledge on the subject on one hand, and on the other — will provide trustable and accessible proof to all market participants on research results conducted throughout their lifecycle.
Attention. There is a risk that unverified members are not actually members of the team
ARNA Genomics is developing a blockchain technology called ARNA Panacea. That blockchain features a data storage system and ecosystem catered towards the world of medical research. Researchers are incentivized to share data with the platform, while regulators can view data as evidence that a particular trial or test was successful. ARNA Genomics, prior to creating this blockchain platform, has been heavily involved with creating early detection tests for cancer – including breast cancer tests. ARNA Panacea is designed to feature research from its early cancer detection tests – as well as the tests created by medical research companies worldwide.
This offer is based on information provided solely by the offeror and other publicly available information. The token sale or exchange event is entirely unrelated to ICOholder and ICOholder has no involvement in it (including any technical support or promotion). Token sales listed from persons that ICOholder has no relationship with are shown only to help customers keep track of the activity taking place within the overall token sector. This information is not intended to amount to advice on which you should rely. You must obtain professional or specialist advice or carry out your own due diligence before taking, or refraining from, any action on the basis of the content on our site. Any terms and conditions entered into by contributors in respect of the acquisition of Tokens are between them and the issuer of the Token and ICOholder is not the seller of such Tokens. ICOholder has no legal responsibility for any representations made by third parties in respect of any Token sale and any claim for breach of contract must also be made directly against the Token issuing entity listed herein.
If you have any concerns about the nature, propriety or legality of this token sale or the persons involved in it please contact [email protected] with detailed information about your concerns.